Abstract
Recent advances in the efficiency and economy of genomic sequencing have propelled the growth of personalized medicine. Genetic screening for cancer susceptibility (e.g., BRCA1/2 testing) is one evidence-based application of “personalized medicine” that improves patient survival.1 However, most individuals and families in whom hereditary breast cancer is suspected do not have a BRCA1/2 mutation. Mutations in other genes (e.g., PTEN, TP53, PALB2, and CHEK2) have been associated with elevated risks of breast cancer.
Full Text
Published Version (
Free)
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call